Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Erba · SciRah

Researcher profile · Semantic Scholar

H. Erba

Share profile

H. Erba — researcher profile on SciRah

h-index: 59
Works: 391
Citations: 16K

Most-cited papers

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
H. Erba, P. Montesinos, Hee-Je Kim, E. Patkowska +18 more
2023The Lancet329 citations
Semantic Scholar
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
T. Shanafelt, X. V. Wang, C. Hanson, E. Paietta +18 more
2022Blood231 citations Open access
Semantic Scholar
Acute myeloid leukaemia.
C. Dinardo, H. Erba, S. Freeman, A. Wei
2023The Lancet191 citations Open access
Semantic Scholar
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia
A. Advani, A. Moseley, K. O'Dwyer, B. Wood +15 more
2022Journal of Clinical Oncology87 citations Open access
Semantic Scholar
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes
A. Nazha, R. Komrokji, M. Meggendorfer, Xuefei Jia +23 more
2021Journal of Clinical Oncology69 citations Open access
Semantic Scholar
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
H. Erba, A. Fathi, G. Issa, J. Altman +15 more
2022Blood67 citations Open access
Semantic Scholar
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
Sara Zarnegar-Lumley, T. Alonzo, R. Gerbing, M. Othus +24 more
2023Blood Advances65 citations Open access
Semantic Scholar
Dasatinib/Prednisone Induction Followed by Blinatumomab/Dasatinib in Ph+ Acute Lymphoblastic Leukemia.
A. Advani, A. Moseley, K. O'Dwyer, B. Wood +13 more
2022Blood Advances63 citations Open access
Semantic Scholar
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.
A. Advani, E. Larsen, K. Laumann, S. Luger +19 more
2021Blood Advances55 citations Open access
Semantic Scholar
Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.
M. Wieduwilt, Jun Yin, O. Kour, Rebecca Teske +13 more
2023Journal of Clinical Oncology48 citations
Semantic Scholar
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy
J. Woyach, A. Ruppert, N. Heerema, Wei-Qiang Zhao +23 more
2021Blood48 citations Open access
Semantic Scholar
Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.
J. Woyach, Gabriela E. Perez Burbano, A. Ruppert, Cecelia R. Miller +28 more
2024Blood42 citations Open access
Semantic Scholar
Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib.
V. Wang, C. Hanson, R. Tschumper, C. Lesnick +18 more
2021Blood39 citations Open access
Semantic Scholar
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia
L. Dillon, J. Higgins, Hassan Nasif, M. Othus +9 more
2023Haematologica35 citations Open access
Semantic Scholar
Standard versus high-dose cytarabine with or without vorinostat for AML
G. Garcia-Manero, N. Podoltsev, M. Othus, J. Pagel +22 more
2023Leukemia30 citations
Semantic Scholar
S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML
H. Erba, P. Montesinos, R. Vrhovac, E. Patkowska +16 more
2022HemaSphere27 citations Open access
Semantic Scholar
Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
N. Daver, P. Montesinos, A. Aribi, G. Marconi +36 more
2022Blood23 citations Open access
Semantic Scholar
Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part
G. Garcia-Manero, Amanda C. Przespolewski, Yasmin M. Abaza, M. Byrne +6 more
2022Blood18 citations Open access
Semantic Scholar
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia
Lori S. Muffly, Jun Yin, S. Jacobson, Anna K. M. Wall +11 more
2022Blood Advances18 citations Open access
Semantic Scholar
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study
I. Aldoss, Jun Yin, Anna K. M. Wall, K. Mrózek +12 more
2022Blood Advances18 citations Open access
Semantic Scholar
A Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
B. Jonas, Jing-Zhou Hou, G. Roboz, Caroline Alvares +11 more
2023Hematological Oncology17 citations Open access
Semantic Scholar
Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)
G. Garcia-Manero, H. Erba, S. Sanikommu, J. Altman +9 more
2021Blood17 citations Open access
Semantic Scholar
S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
M. Litzow, Zhuo-Xin Sun, R. Mattison, E. Paietta +33 more
2023HemaSphere16 citations Open access
Semantic Scholar
Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia
N. Daver, J. Zeidner, J. Yuda, J. Watts +21 more
2023Blood16 citations Open access
Semantic Scholar
The New NCI Precision Medicine Trials
L. Harris, C. Blanke, H. Erba, J. Ford +21 more
2023Clinical Cancer Research16 citations Open access
Semantic Scholar
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
K. Pratz, J. Kaplan, M. Levy, D. Bixby +15 more
2022Haematologica16 citations Open access
Semantic Scholar
Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
R. Little, M. Othus, S. Assouline, S. Ansher +29 more
2022Blood16 citations Open access
Semantic Scholar
Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial
S. Luger, Zhuo-Xin Sun, Ryan J. Mattison, E. Paietta +32 more
2023Blood15 citations Open access
Semantic Scholar
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
C. Dinardo, E. Stein, A. Pigneux, J. Altman +12 more
2021Leukemia15 citations Open access
Semantic Scholar
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).
J. Woyach, Jun Yin, Jennifer R. Brown, S. Dinner +16 more
2023Journal of Clinical Oncology14 citations
Semantic Scholar
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
N. Daver, A. Aribi, P. Montesinos, G. Roboz +28 more
2021Blood14 citations
Semantic Scholar
Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
M. Othus, G. Garcia-Manero, J. Godwin, J. Weick +3 more
2022Haematologica13 citations Open access
Semantic Scholar
P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
A. Fathi, Eunice S. Wang, G. Issa, J. Altman +21 more
2023HemaSphere12 citations Open access
Semantic Scholar
Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
A. Advani, A. Moseley, Kristin O'Dwyer, B. Wood +15 more
2023Blood12 citations Open access
Semantic Scholar
S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703
M. Wieduwilt, Jun Yin, O. Kour, Rebecca Teske +13 more
2023HemaSphere9 citations Open access
Semantic Scholar
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care
B. Tomlinson, M. D. De Lima, C. Cogle, M. Thompson +21 more
2023Transplantation and Cellular Therapy9 citations Open access
Semantic Scholar
Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival
M. Levis, H. Erba, P. Montesinos, R. Vrhovac +17 more
2022Blood9 citations
Semantic Scholar
AML-475 Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML
H. Erba, Eunice S. Wang, G. Issa, J. Altman +27 more
2023Clinical Lymphoma, Myeloma & Leukemia8 citations
Semantic Scholar
Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia.
A. Zeidan, A. Fathi, G. Issa, H. Erba +6 more
2023Journal of Clinical Oncology7 citations
Semantic Scholar
Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial
R. Schlenk, P. Montesinos, Antonio Romero-Aguilar, R. Vrhovac +17 more
2022Blood7 citations
Semantic Scholar
AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3-Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML).
H. Erba, P. Montesinos, R. Vrhovac, E. Patkowska +16 more
2022Clinical Lymphoma, Myeloma & Leukemia6 citations
Semantic Scholar
Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)
A. Wei, M. Breccia, M. Ooi, M. T. Cedena Romero +8 more
2021Blood6 citations
Semantic Scholar
A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
N. Pemmaraju, G. Marconi, E. Todisco, P. Montesinos +22 more
2021Blood6 citations Open access
Semantic Scholar
Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3-ITD+ AML Patients (pts
A. Perl, H. Erba, P. Montesinos, R. Vrhovac +17 more
2023Blood5 citations
Semantic Scholar
Characteristics and Prognostic Effects of DNMT3A Co-Mutations
Alireza Torabi, T. Alonzo, M. Othus, R. Gerbing +16 more
2022Blood5 citations Open access
Semantic Scholar
Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#
D. Stephens, A. Moseley, B. Hill, J. Pagel +10 more
20215 citations
Semantic Scholar
P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL
M. Levis, H. Erba, P. Montesinos, R. Vrhovac +17 more
2023HemaSphere4 citations Open access
Semantic Scholar
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients
E. Pogosova-Agadjanyan, X. Hua, M. Othus, F. Appelbaum +15 more
2023Biomarker Research4 citations Open access
Semantic Scholar
Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)
T. Kadia, C. Benton, H. Erba, M. Gandhi +11 more
2022Blood4 citations Open access
Semantic Scholar
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
J. Mccloskey, V. Pullarkat, G. Mannis, Tara L. Lin +9 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Litzow×16
Invite
M. Litzow — researcher profile on SciRah
P. Montesinos×13
Invite
P. Montesinos — researcher profile on SciRah
R. Stone×13
Invite
R. Stone — researcher profile on SciRah
M. Othus×12
Invite
M. Othus — researcher profile on SciRah

×11

Invite

S. Luger — researcher profile on SciRah

Invite

M. Levis — researcher profile on SciRah

Invite

A. Advani — researcher profile on SciRah

Invite

M. Sekeres — researcher profile on SciRah

Invite

M. Tallman — researcher profile on SciRah

Geoffrey L. Uy×8

Invite

Geoffrey L. Uy — researcher profile on SciRah

A. Lesegretain×7

Invite

A. Lesegretain — researcher profile on SciRah

Invite

A. Perl — researcher profile on SciRah